Viewing Study NCT05036005

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:28 AM
Ignite Modification Date: 2026-06-01 @ 9:50 AM
Study NCT ID: NCT05036005
Status: UNKNOWN
Last Update Posted: 2023-04-18
First Post: 2021-08-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
Sponsor: Institut fuer Frauengesundheit
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Breast Neoplasms View
None Breast Cancer Female View
None HER2-positive Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Ontruzant View
None Trastuzumab View
None Pertuzumab View
None neoadjuvant chemotherapy View